After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and ...

Dr. Reddy’s US generics business drags Q1 earnings, eyes weight-loss drug launch in 87 countries The drugmaker plans to launch Semaglutide in 87 countries next year, including those where ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure. This effect happened through direct action on the heart muscle and ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Health Canada reviewing five applications for generic semaglutide drugs.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

Manjaro outperforms Wegovy in treating obesity complications in Korea Eli Lillys tirzepatide shows significant advantage over Novo Nordisks semaglutide in managing obesity-related health issues.

In a 36-week study, semaglutide was found to aid in weight loss for people with schizophrenia without worsening psychotic symptoms. Participants lost nearly 14% of body weight, and there was an ...

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass.